**Funding Opportunity:** OICR Cancer Therapeutics Innovation Pipeline – Early Accelerator Projects

**Letter of Intent deadline:** August 13, 2018

**Funding period:** April 1, 2019 – March 31, 2020

**Instructions:** Refer to section 2 of the OICR Cancer Therapeutics Innovation Pipeline Request for Applications for further instructions. All sections are mandatory and must be completed using 11-point Arial font and single spacing. Margins cannot be modified and word limits must be strictly followed. Submit as one PDF to [scientificsecretariat@oicr.on.ca](mailto:scientificsecretariat@oicr.on.ca). File must be labelled as follows:

PI Last Name CTIP LOI.pdf.

|  |  |  |
| --- | --- | --- |
| **Applicant information** | | |
| **Project title:** | | |
| 1. **Has this work been published/patented?**  Yes  No 2. If yes, please describe how this proposal builds upon the published/patented work.: | | |
| **Principal Investigator(s)** | | |
| **Name** | **Institution** | **Email** |
|  |  |  |
|  |  |  |
| **Co-Investigator(s)** (if applicable) | | |
| **Name** | **Institution** | **Email** |
|  |  |  |
|  |  |  |
|  |  |  |

|  |
| --- |
| **Project details (max. 25 words per heading)** |
| **Target and/or pathway** |
| **Mechanistic class** (e.g., kinase, protein-protein interaction, GPCR, protease, histone methyltransferase, etc.) |
| **Cancer cell type(s) targeted** |

|  |
| --- |
| **Background (max. 400 words):** Provide a summary of your work and any relevant published work which describes unmet need, target validation, therapeutic rationale, and differentiation from other approaches. |

|  |
| --- |
| **Research plan (max. 400 words):** Describe your research plan. Describe the development and validation of the primary screening assay, screening strategy and potential major challenges. |

|  |
| --- |
| **Proposed budget (max. 100 words; numbers are considered words):** Describe the high-level budgetary requirements and any current funding allocated to the project. |

|  |  |  |
| --- | --- | --- |
| **Relevant references (max. five references):** List the references sited above. | | |
| **Primary author** | **Title** | **PubMed ID (PMID) or Digital Object Identifier (DOI)** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |